Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/178572
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Agnelli, Giancarlo | - |
dc.contributor.author | Buller, Harry R. | - |
dc.contributor.author | Cohen, Alexander | - |
dc.contributor.author | Curto, Madelyn | - |
dc.contributor.author | Gallus, Alexander S. | - |
dc.contributor.author | Johnson, Margot | - |
dc.contributor.author | Porcari, Anthony | - |
dc.contributor.author | Raskob, Gary E. | - |
dc.contributor.author | Weitz, Jeffrey I. | - |
dc.contributor.author | Riera Mestre, Antoni | - |
dc.contributor.author | AMPLIFY-EXT Investigators | - |
dc.date.accessioned | 2021-06-17T17:19:25Z | - |
dc.date.available | 2021-06-17T17:19:25Z | - |
dc.date.issued | 2012-12-08 | - |
dc.identifier.issn | 0028-4793 | - |
dc.identifier.uri | http://hdl.handle.net/2445/178572 | - |
dc.description.abstract | Background: Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism. Methods: in this randomized, double-blind study, we compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy and for whom there was clinical equipoise regarding the continuation or cessation of anticoagulation therapy. The study drugs were administered for 12 months. Results: a total of 2486 patients underwent randomization, of whom 2482 were included in the intention-to-treat analyses. Symptomatic recurrent venous thromboembolism or death from venous thromboembolism occurred in 73 of the 829 patients (8.8%) who were receiving placebo, as compared with 14 of the 840 patients (1.7%) who were receiving 2.5 mg of apixaban (a difference of 7.2 percentage points; 95% confidence interval [CI], 5.0 to 9.3) and 14 of the 813 patients (1.7%) who were receiving 5 mg of apixaban (a difference of 7.0 percentage points; 95% CI, 4.9 to 9.1) (P<0.001 for both comparisons). The rates of major bleeding were 0.5% in the placebo group, 0.2% in the 2.5-mg apixaban group, and 0.1% in the 5-mg apixaban group. The rates of clinically relevant nonmajor bleeding were 2.3% in the placebo group, 3.0% in the 2.5-mg apixaban group, and 4.2% in the 5-mg apixaban group. The rate of death from any cause was 1.7% in the placebo group, as compared with 0.8% in the 2.5-mg apixaban group and 0.5% in the 5-mg apixaban group. Conclusions: extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding. (Funded by Bristol Myers Squibb and Pfizer; AMPLIFY-EXT ClinicalTrials.gov number, NCT00633893). | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Massachusetts Medical Society | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1056/NEJMoa1207541 | - |
dc.relation.ispartof | New England Journal of Medicine, 2012, vol. 368, num. 8, p. 699-708 | - |
dc.relation.uri | https://doi.org/10.1056/NEJMoa1207541 | - |
dc.rights | (c) Massachusetts Medical Society, 2012 | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Fibrinolítics | - |
dc.subject.classification | Tromboembolisme | - |
dc.subject.classification | Administració de medicaments | - |
dc.subject.other | Fibrinolytic agents | - |
dc.subject.other | Thromboembolism | - |
dc.subject.other | Administration of drugs | - |
dc.title | Apixaban for extended treatment of venous thromboembolism | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 661997 | - |
dc.date.updated | 2021-06-17T17:19:25Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 23216615 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
661997.pdf | 412.34 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.